Everolimus and enteric-coated mycophenolate sodium Ab initio after liver transplantation: Midterm results by Manzia, TM et al.
Everolimus and Enteric-Coated Mycophenolate Sodium Ab Initio after
Liver Transplantation: Midterm Results
T.M. Manzia, D. Sforza, R. Angelico, M.I. Bellini, P. Ciano, M. Manuelli, L. Toti, and G. Tisone
ABSTRACT
Background and aim. Everolimus (EVR) use in liver transplantation (OLT) has been
prescribed with calcineurin inhibitors (CNIs), steroids, and monoclonal antibodies. The
aim of our study was to evaluate the safety, feasibility, and impact on renal function of
EVR ab initio, in combination with enteric-coated mycophenolate sodium (EC-MPS)
without the use of induction treatment, steroids, or CNIs.
Patients and methods. We retrospective analyzed nine consecutive patients who
underwent OLT at our institution. The initial dose of EVR (1.5 mg/d) was adjusted to
achieve trough levels of 8 to 12 ng/mL. EC-MPS introduced at 1080 mg/d was maintained
at the same dose over time.
Results. At a mean follow-up of 21.48 (standard deviation [SD] 1.4) months from OLT,
7/9 recipients were alive with stable graft function. The 2-year patient and graft survivals
were 77%. One recipient died due to cerebral hemorrhage and one, lung failure. No
clinical evidence of an acute rejection episode was observed. Mean estimated glomerular
filtration rate value, according to the Modification of Diet in Renal Disease formula
increased from 59.5 (SD 9.89) mL/min/1.73 m2 at OLT to 100.2 (SD 47.5) mL/min/1.73 m2
(P! .03) after 12 months and 98.71 (SD 33.74) mL/min/1.73 m2 (P! .03) after 24 months’
follow-up.
Conclusion. A double immunosuppression therapy with EVR and EC-MPS ab initio
seemed to be efficacions and safe, representing a valid alternative to CNIs to prevent renal
failure after OLT.
IMMUNOSUPPRESSIVE THERAPY based on cal-cineurin inhibitors (CNIs) in liver transplantation
(OLT) reduces the risk of rejection but is associated with
side effects including renal failure, neurotoxicity, cardiovas-
cular complications, hypertension, and diabetes mellitus.1
Chronic renal dysfunction (CRD) among OLT recipients
shows a cumulative incidence of 20% within 3 years and a
fourfold increased risk of death.2–4 CRD among OLT
recipients has multifactorial origins: female sex, renal dis-
ease pretransplantation, primary graft dysfunction, periop-
erative acute renal damage, recipient age, hepatitis C,
hypertension, diabetes mellitus. The prescription of CNIs
seems to be the only modifiable risk factor.5
CNIs lead to acute nephropathy by renal arteriolar
vasoconstriction and tubular vacuolization; pathological
findings can be reversed by CNI withdrawal. In contrast, the
chronic CNI-induced nephrotoxicity, which is characterized
by arteriolopathy and tubulointerstitial fibrosis, develops
irreversible structural damage.6 CNI therapy is also respon-
sible for new-onset diabetes and hypertension, important
risk factors for CRD.7
The current clinical challenge is therefore to develop
regimens that maintain high rates of efficacy while minimiz-
ing side effects. Everolimus (EVR; Certican; Novartis,
Basel, Switzerland), a proliferation signal inhibitor (PSI),8
seems to not increase the risk of renal dysfunction while
maintaining excellent efficacy as an immunosuppressant. A
few studies have shown the safety and efficacy of PSI in
midterm results9,10; however, there was no renal functional
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improvement after PSI introduction,9,11 possibly due to the
onset of irreversible renal “stigmata” from chronic CNI use.
Thus, it seems reasonable to introduce EVR earlier with
CNI avoidance immediately after OLT to minimize the risk
of renal dysfunction particularly among patients at high risk
of renal failure. Based on the dogma of “earlier is better,”
the aim of our study was to evaluate the safety, feasibility,
and renal functional impact of EVR ab initio, as the main
drug in OLT, in combination with enteric-coated mycophe-
nolate sodium (EC-MPS) without the use of induction
antibody treatment, steroids and CNIs.
PATIENTS AND METHODS
We retrospective analyzed nine patients who consecutively under-
went OLT between September 2009 and February 2010. The
regimen consisted of EVR and EC-MPS ab initio. No patients
received an induction therapy (basiliximab or daclizumab) and/or
steroids. The initial EVR dose was 1.5 mg/d, seeking to achieve a
C0 level of 8 to 12 ng/mL within 7 postoperative days (POD). The
EVR dose was then modified to achieve an EVR target trough
level of 6 to 10 ng/mL. EC-MPS was introduced and maintained at
1080 mg per day. EC-MPS and/or EVR administration was modi-
fied in the presence of side effects and/or the need for more intense
immunosuppression.
The primary endpoint of the study was to evaluate the safety and
efficacy of a CNI-free regimen without induction or steroid in de
novo OLT recipients. The second aim was to assess renal function
expressed as estimated glomerular filtration rate (EGFR) using the
Modification of Diet in Renal Disease (MDRD) formula in OLT
recipients who received EVR and EC-MPS ab initio.
Clinical and laboratory data were prospectively recorded at
baseline as well as at months 3, 12, and 24 after OLT. The collected
data included hematology and biochemistry tests and EVR trough
levels.
EVR was assayed on aTDxFLx analyzer (Abbott Diagnostic, Ill,
USA) using a Certican homogeneous fluorescence polarization
immunoassay system.
Data were retrieved from a prospective database (Microsoft
Access 2.0, Microsoft Corporation, USA). Categorical metrics were
analysed using Fisher exact test for simple cross tables; continuous
data of normal distribution, by the parametric Student t test using
mean values " standard deviations (SD). A P value of #.05 was
considered significant. Graft and patient survival were evaluated
using the Kaplan-Meier method.
RESULTS
Demographics Characteristics of the Study Population
Nine consecutive patients (eight male, one female) who
underwent OLT at our institution between September 2009
and February 2010 received EVR and EC-MPS ab initio.
Their indications for OLT are reported in Table 1. At the
time of OLT the mean age was 48.6 " 5.7 years and mean
Model for End-stage Liver Disease (MELD) score was 22
(SD 6.4). Three recipients (33.3%) were hospitalized before
OLT. The mean eGRF value according to MDRD was 59.5
(SD 9.89) mL/min/1.73 m2 and 2 patients (22.2%) required
dialysis for hepatorenal syndrome. None of the recipients
had a significant additional medical history such as leuko-
penia, diabetes or dyslipidemia. All OLT were performed
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using the venovenous bypass and all of them, a whole organ
graft, except one who received a right split liver from a
compatible group donor. The mean donor age was 46.4 (SD
19.8) years and the mean cold and warm ischemic times
were 402.4 " 58.1 and 40.8 " 7.7 minutes respectively.
Safety and Tolerability
After a mean of 21.4 (SD 1.4) months from OLT, 7/9
recipients (77.7%) were alive with stable graft function.
One recipient died due to a cerebral hemorrhage and one,
to lung failure after 4 and 35 days, respectively; both of
them experienced pre-OLT dialysis due to renal failure.
Regimen and Graft Function
Within the 6 months, the mean EVR trough levels were
between 8 and 12 ng/mL initially trending to # 10 ng/mL.
No patients required EVR therapy discontinuation during
the follow-up. EC-MPS was maintained at 1080 mg per day.
Neither graft lost nor clinical evidence of an acute rejection
episode or, liver dysfunction was observed at any of the
considered times. At 24 months’ follow-up, alanine amino-
transferase and gamma-glutamyl-transferase were 61 (SD
66.46) UI/L and 100 (SD 21.9) UI/L respectively.
Renal Function
At OLT, two patients presented severe renal impairment
requiring replacement therapy; both continued dialysis af-
ter OLT. In the early posttransplant period one patient with
severe hepatorenal syndrome before OLT (eGFR ! 36
mL/min/1.73 m2) developed acute renal dysfunction (eGFR !
19.41 mL/min/1.73 m2) that resolved after 30 days (eGFR of
68 mL/min/1.73 m2) without requiring any dialysis. At 22
months’ follow-up the patient was in good clinical condition
with stable renal function (eGFR ! 84 mL/min/1.73 m2).
The overall mean eGRF value increased from 59.5 (SD
9.89) mL/min/1.73 m2 at OLT to 113.63 (SD 63.5) mL/min/
1.73 m2 (P ! .04) at 3 months, remaining stable during the
follow-up: eGFR ! 100.2 " 47.5 mL/min/1.73 m2 (P ! NS)
at 12 months and 98.71 " 33.74 mL/min/1.73 m2 (P ! NS)
at 24 months.
Adverse Events
In the early posttransplant period, one patient developed a
inferior vena cava thrombosis, that resolved with anticoag-
ulant therapy. One patient required EC-MPS withdrawal
after 9 months for severe leukopenia (white blood cell
count # 2000/!L) but remained under EVR monotherapy
with stable graft function.
Two patients developed pneumonia immediately after
OLT that resolved with antibiotic therapy; there was no
other infection including that due to cytomegalovirus. One
patient presented severe lower limb and eyelid edema, but
no evidence of mucositis/oral ulcer or dermatitis. Two
recipients (22.2%) experienced a surgical wound dehis-
cence, developing an incisional hernia. No gastrointestinal
side effects such as nausea, diarrhea, or abdominal pain
were observed. Dyslipidemia requiring medical therapy was
reported in three cases.
DISCUSSION
PSI acts at a later stage in the cell cycle blocking the
proliferation signal provided by growth factors, thereby
preventing cells from entering the S phase. The antiprolif-
erative effects of PSI are not limited to the immune system
but also to nonhematopoietic elements including vascular
smooth muscle cells. The safety and efficacy of EVR have
been demonstrated in renal11 and heart12 transplant recip-
ients. It is currently used in these patients to reduce CNI
toxicity and/or prevent CRD. There are few data concern-
ing the use of EVR in OLT recipients. Levy et al reported
no significant changes in laboratory parameters, infection
rates and an acceptable safety and toxicity profile of EVR in
combination with cyclosporine.13,14 Preliminary studies of
PSI for a maintenance regimen in OLT recipients have
mainly focused on sirolimus (SRL) to treat patients with
CNI-related CRD.15,16
These experiences have demonstrated that CNI minimi-
zation associated with SRL or conversion from a CNI to
SRL-based regimen was feasible. This strategy was associ-
ated with 5% to 15% risk of acute rejection with a variable
degree of improvement in renal function according to the
baseline creatinine clearance,17–20 CNI-related renal dis-
ease, and time from OLT.21 Nevertheless, more recent data
have suggested the efficacy of SRL-based regimens on
long-term renal function post OLT.22–25
CNI produces acute nephropathy characterized by vaso-
constriction of renal arterioles, as manifested clinically by
reduced glomerular filtration, hyperkalemia, hypertension,
increased sodium reabsorption, and oliguria.6 The CNI-
induced chronic renal damage is characterized by the
development of arteriolopathy and tubulointerstitial fibro-
sis, which is irreversible and may lead to end-stage nephrop-
athy.6 The toxicity may be reversed when CNI therapy is
reduced or withdrawn. Therefore, benefit from PSI therapy
may be expected only for early CNI minimization/with-
drawal or avoidance ab initio, namely while pathological
changes are still reversible. In OLT, most series have
reported EVR used as maintenance therapy seeking to
improve renal function but not CRD prevention.5,7,12,26
In this scenario, the purpose of our study was to evaluate
whether a CNI-free regimen using EVR and EC-MPS as
the main drugs ab initio without induction or steroids was
safe and effective and ensured preservation of renal func-
tion among OLT recipients. Our data showed PSI use ab
initio to be safe in terms of patients and graft survival and
acute cellular rejection rate. Furthermore no patients with
baseline normal renal function developed post-OLT renal
dysfunction that required kidney replacement therapy. Only
one patient with hepatorenal syndrome before OLT devel-
oped severe renal impairment immediately there after,
which never required dialysis and recovered within 30 POD.
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These results suggested that EVR and EC-MPS ab initio
may be used to prevent renal dysfunction especially among
patients who showed renal impairment before surgery.
As reported by Masetti23 and Sanchez Fructuoso,24 he-
matologic side effects of the antimetabolite in association of
PSI were rare. In our cohort only one patient who devel-
oped leukopenia after 9 months completely recovered after
EC-MPS withdrawal, suggesting the hematotoxicity was
rare and easily managed. A few patients experienced other
side effects,27–33 including dyslipidemia (n ! 3), wound
healing (n ! 2), and lower limb edema (n ! 1), that
completely recovered after dose adjustment and conserva-
tive management.
In conclusion, this series explores EVR associated with
EC-MPS without CNI, induction therapy, or steroid in de
novo OLT recipients. Our data suggested that this feasible
and safe regimen was a valid alternative for patients who
require a CNI-free protocol due to renal dysfunction before
transplantation.
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